Diabetes & Metabolic Disease
The rate of diabetes (type II) is increasing hand in hand with obesity and now poses a major health problem in most developed countries, including New Zealand. Diabetes accelerates many other disease processes, including cardiovascular disease, but the mechanisms linking the metabolic changes associated with obesity through to diabetes and cardiovascular disease are still far from clear.
The Maurice Wilkins Centre research programme in diabetes and related metabolic conditions aims to identify pathways to new treatments for diabetes and its associated complications.
THE MAURICE WILKINS CENTRE UNDERTAKES RESEARCH IN THE FOLLOWING AREAS
Using genetic risk for metabolic disease to understand disease mechanisms and guide treatment
Obesity and type-2 diabetes rates in Māori and Pacific peoples in New Zealand are 2-3 times higher than for the general population, representing a major health challenge of particular importance to the country.
Therapeutics for Metabolic Disease
The Maurice Wilkins Centre’s Therapeutics for Metabolic Disease Flagship focuses on the development of treatments that target metabolic hormonal systems in order to treat human metabolic disorders.
Hormones controlling metabolism
Human metabolic disorders are often associated with defects in the production or release of key metabolic hormones.
The role of genetics in the etiology and management of obesity and diabetes in NZ populations
Rates of obesity and type-2 diabetes are higher in Māori and Pacific populations than for the general population in New Zealand. This therefore represents a major health challenge of particular importance to the country.